BXT 253
Alternative Names: BXT-253Latest Information Update: 30 Jun 2023
At a glance
- Originator BioXyTran
- Class Antianaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Anaemia
Most Recent Events
- 11 May 2023 BXT 253 is available for licensing as of 30 Jun 2023. https://www.bioxytraninc.com (BioXyTran pipeline, May 2023)
- 11 May 2023 Early research in Anaemia in USA (unspecified route) (BioXyTran pipeline, May 2023)
- 11 May 2023 BioXyTran plans a preclinical trial for Anaemia in USA (unspecified route) (BioXyTran pipeline, May 2023)